Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash from Investing Activities: 2017-2024

Historic Cash from Investing Activities for Solid Biosciences (SLDB) over the last 8 years, with Dec 2024 value amounting to $38.6 million.

  • Solid Biosciences' Cash from Investing Activities fell 14.86% to $38.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$16.1 million, marking a year-over-year decrease of 266.02%. This contributed to the annual value of -$16.1 million for FY2024, which is 266.02% down from last year.
  • Per Solid Biosciences' latest filing, its Cash from Investing Activities stood at $38.6 million for Q4 2024, which was up 451.02% from -$11.0 million recorded in Q3 2024.
  • Over the past 5 years, Solid Biosciences' Cash from Investing Activities peaked at $66.1 million during Q4 2022, and registered a low of -$72.5 million during Q3 2021.
  • In the last 3 years, Solid Biosciences' Cash from Investing Activities had a median value of $4.9 million in 2022 and averaged $4.4 million.
  • In the last 5 years, Solid Biosciences' Cash from Investing Activities tumbled by 90,537.50% in 2021 and then skyrocketed by 107,937.14% in 2022.
  • Quarterly analysis of 5 years shows Solid Biosciences' Cash from Investing Activities stood at -$60,000 in 2020, then spiked by 50,393.33% to $30.2 million in 2021, then skyrocketed by 119.05% to $66.1 million in 2022, then crashed by 31.47% to $45.3 million in 2023, then dropped by 14.86% to $38.6 million in 2024.
  • Its Cash from Investing Activities stands at $38.6 million for Q4 2024, versus -$11.0 million for Q3 2024 and -$5.2 million for Q2 2024.